BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26408409)

  • 1. HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals.
    Cuevas A; Fernández C; Ferrada L; Zambrano T; Rosales A; Saavedra N; Salazar LA
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):292-7. PubMed ID: 26408409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
    Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
    Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender-Specific Association Between ABCC2 -24C>T SNP and Reduction in Triglycerides in Chilean Patients Treated With Atorvastatin.
    Prado Y; Arencibia A; Zambrano T; Salazar LA
    Basic Clin Pharmacol Toxicol; 2018 May; 122(5):517-522. PubMed ID: 29178257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects.
    Prado Y; Zambrano T; Salazar LA
    J Clin Pharm Ther; 2018 Feb; 43(1):87-91. PubMed ID: 28833323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
    Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Polymorphisms Affect the Effectiveness of Atorvastatin in Treating Ischemic Stroke Patients.
    Yue YH; Bai XD; Zhang HJ; Li YM; Hu L; Liu LY; Mao JP; Yang XY; Dila NM
    Cell Physiol Biochem; 2016; 39(2):630-8. PubMed ID: 27415775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.
    Kadam P; Ashavaid TF; Ponde CK; Rajani RM
    J Clin Pharm Ther; 2016 Jun; 41(3):329-33. PubMed ID: 26932749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
    Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
    DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
    Rosales A; Alvear M; Cuevas A; Saavedra N; Zambrano T; Salazar LA
    Clin Chim Acta; 2012 Feb; 413(3-4):495-501. PubMed ID: 22120734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of
    Mladenovska K; Grapci AD; Vavlukis M; Kapedanovska A; Eftimov A; Geshkovska NM; Nebija D; Dimovski AJ
    Pharmazie; 2017 May; 72(5):288-295. PubMed ID: 29441875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of age and gender on the relationship between HMGCR promoter-911 SNP (rs33761740) and serum lipids in patients with coronary heart disease.
    Akadam-Teker B; Kurnaz O; Coskunpinar E; Daglar-Aday A; Kucukhuseyin O; Cakmak HA; Teker E; Bugra Z; Ozturk O; Yilmaz-Aydogan H
    Gene; 2013 Oct; 528(2):93-8. PubMed ID: 23933271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
    Cerda A; Genvigir FD; Arazi SS; Hirata MH; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    Clin Chim Acta; 2010 May; 411(9-10):631-7. PubMed ID: 20064494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mendelian randomization study of lipid metabolism characteristics and migraine risk.
    Hong P; Han L; Wan Y
    Eur J Pain; 2024 Jul; 28(6):978-986. PubMed ID: 38183343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential associations of statin treatment and polymorphism in genes coding for HMGCR and PCSK9 to risk for insomnia.
    Alsehli AM; Rukh G; Clemensson LE; Ciuculete DM; Tan X; Al-Sabri MH; Williams MJ; Benedict C; Schiöth HB
    Front Biosci (Landmark Ed); 2021 Dec; 26(12):1453-1463. PubMed ID: 34994160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.